Metabolism and Sleep Apnea Treatment

Description

The purpose of this research study is to see if obstructive sleep apnea (OSA) is associated with abnormalities in fat metabolism. Through this research study, the Investigator will evaluate how fat is metabolized in people with and without sleep apnea, what substances the fat tissue releases, and how these substances might change the way the body uses energy and sugar.

Conditions

Obstructive Sleep Apnea, Fat Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to see if obstructive sleep apnea (OSA) is associated with abnormalities in fat metabolism. Through this research study, the Investigator will evaluate how fat is metabolized in people with and without sleep apnea, what substances the fat tissue releases, and how these substances might change the way the body uses energy and sugar.

Metabolism and Sleep Apnea Treatment

Metabolism and Sleep Apnea Treatment

Condition
Obstructive Sleep Apnea
Intervention / Treatment

-

Contacts and Locations

Miami

University of Miami, Miami, Florida, United States, 33143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age between 18-70 years
  • * Ability to provide consent
  • * Body Mass Index (BMI) \> 40 kg/m2
  • * Prevalent myocardial infarction, coronary revascularization, heart failure, and stroke
  • * Type 1 or Type 2 diabetes mellitus
  • * Current or prior use of PAP or oral appliance therapy for OSA
  • * Use of oral corticosteroids
  • * Unstable medical conditions that may preclude enrollment in the protocol such as: uncontrolled angina and/or congestive heart failure, uncontrolled blood pressure or resistant hypertension, severe chronic obstructive pulmonary disease, cancer, and active psychiatric disease (e.g., major depression)
  • * Other sleep disorders (e.g., circadian rhythm disorder, self-reported habitual sleep duration \< 6h)
  • * Use of supplemental oxygen during wakefulness or sleep
  • * Central sleep apnea, obesity hypoventilation syndrome or Cheyne-Stokes respiration based on the home sleep test
  • * Resting awake Oxygen Saturation (SpO2) \< 90%
  • * BMI: ≥ 40 kg/m2
  • * Type 1 or Type 2 diabetes mellitus
  • * Current use of PAP or oral appliance therapy for OSA
  • * Commercial driver or report of motor vehicle accident or near-miss due to sleepiness within the 2 previous years
  • * Epworth sleepiness score of 18 or more
  • * Use of oral corticosteroids
  • * Participation in another clinical trial
  • * Unstable medical conditions that may preclude enrollment in the protocol such as: uncontrolled angina and/or congestive heart failure, uncontrolled blood pressure or resistant hypertension, severe chronic obstructive pulmonary disease, cancer, and active psychiatric disease (e.g., major depression)
  • * Other sleep disorders (e.g., circadian rhythm disorder, self-reported habitual sleep duration \< 6h)
  • * Use of supplemental oxygen during wakefulness or sleep
  • * Central sleep apnea, obesity hypoventilation syndrome or Cheyne-Stokes respiration based on the home sleep test
  • * Resting awake SpO2 \< 90%

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Miami,

Naresh Punjabi, MD, PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

2026-09-01